Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EBIT (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of EBIT data on record, last reported at -$43.1 million in Q3 2025.

  • For Q3 2025, EBIT fell 43.62% year-over-year to -$43.1 million; the TTM value through Sep 2025 reached $27.2 million, up 123.18%, while the annual FY2024 figure was -$101.4 million, 11.68% up from the prior year.
  • EBIT reached -$43.1 million in Q3 2025 per STOK's latest filing, down from -$27.3 million in the prior quarter.
  • Across five years, EBIT topped out at $111.2 million in Q1 2025 and bottomed at -$43.1 million in Q3 2025.
  • Average EBIT over 4 years is -$18.6 million, with a median of -$27.2 million recorded in 2023.
  • The widest YoY moves for EBIT: up 492.08% in 2025, down 43.62% in 2025.
  • A 4-year view of EBIT shows it stood at -$27.2 million in 2022, then dropped by 8.87% to -$29.6 million in 2023, then skyrocketed by 53.85% to -$13.7 million in 2024, then tumbled by 215.57% to -$43.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$43.1 million in Q3 2025, -$27.3 million in Q2 2025, and $111.2 million in Q1 2025.